Related Experiment Videos
[ACE inhibitors and heart failure]
1Università degli Studi di Bologna, Istituto di Patologia Speciale Medica e Metodologia Clinica.
Insights
Angiotensin-converting enzyme (ACE) inhibitors significantly improve survival in heart failure patients by dilating blood vessels and modulating harmful neuro-endocrine responses. While several ACE inhibitors exist, individual patient needs should guide drug selection for optimal outcomes.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Heart failure is a significant clinical condition associated with increased morbidity and mortality.
- Neuro-endocrine activation, including the renin-angiotensin-aldosterone system, plays a crucial role in the pathophysiology of heart failure.
Purpose of the Study:
- To review the therapeutic effectiveness of ACE inhibitors in heart failure.
- To discuss the mechanisms of action and available agents in Italy.
Main Methods:
- Review of existing literature on ACE inhibitors in heart failure treatment.
- Analysis of pharmacological characteristics, effectiveness, and tolerability of available ACE inhibitors.
Main Results:
- ACE inhibitors demonstrate considerable therapeutic effectiveness and prolong survival in heart failure patients.
- Benefits are attributed to vasodilation and modulation of neuro-endocrine responses like angiotensin-aldosterone production.
- Four ACE inhibitors (captopril, enalapril, lisinopril, quinapril) are available in Italy with similar efficacy and tolerability.
Conclusions:
- ACE inhibitors are vital in managing heart failure.
- The choice of a specific ACE inhibitor should be individualized based on patient-specific factors and pharmacological properties.
Abstract:
ACE-inhibitors have been shown to have considerable therapeutic effectiveness in the treatment of heart failure and to be able to significantly prolong the survival of treated patients. The benefits of these drugs when used in the treatment of heart failure are due to their vasodilator action on both arterial and venous vessels. An even more relevant mechanism might be the modulation of some neuro-endocrine responses induced by heart failure, such as angiotensin-aldosterone production, which are sometimes excessive or harmful. The molecules presently available in Italy are four (captopril, enalapril, lisinopril, quinapril), endowed with considerably different pharmacological characteristics, but substantially similar as far as effectiveness and tolerability are concerned. Although general guidelines cannot be suggested on the basis of the pharmacological profile alone, the choice of the drug to be used in every single patient with heart failure should be made taking into account the adequacy of the pharmacological properties for the specific situation.